Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.77 USD | -2.36% | -8.13% | +62.80% |
13/05 | Merus Says US FDA Grants Breakthrough Therapy Designation for Petosemtamab | MT |
13/05 | Merus Carcinoma Treatment Awarded US FDA's Breakthrough Therapy Designation | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+62.80% | 262.74Cr | |
+5.33% | 11TCr | |
+12.11% | 11TCr | |
-12.56% | 2.22TCr | |
-3.70% | 2.13TCr | |
-6.03% | 1.9TCr | |
-35.21% | 1.85TCr | |
-10.86% | 1.68TCr | |
+5.10% | 1.39TCr | |
+37.57% | 1.25TCr |
- Stock Market
- Equities
- MRUS Stock
- News Merus N.V.
- BMO Capital Adjusts Price Target on Merus to $47 From $46, Maintains Outperform Rating